ZA974028B - Inhibition of matrix metalloproteinases by 2(w-aroylalkyl)-4-biaryl-4-oxobutyric acids. - Google Patents

Inhibition of matrix metalloproteinases by 2(w-aroylalkyl)-4-biaryl-4-oxobutyric acids.

Info

Publication number
ZA974028B
ZA974028B ZA9704028A ZA974028A ZA974028B ZA 974028 B ZA974028 B ZA 974028B ZA 9704028 A ZA9704028 A ZA 9704028A ZA 974028 A ZA974028 A ZA 974028A ZA 974028 B ZA974028 B ZA 974028B
Authority
ZA
South Africa
Prior art keywords
aroylalkyl
biaryl
inhibition
matrix metalloproteinases
oxobutyric acids
Prior art date
Application number
ZA9704028A
Other languages
English (en)
Inventor
William J Scott
Margaret A Popp
David S Hartsough
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA974028B publication Critical patent/ZA974028B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/90Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46Friedel-Crafts reactions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/88Unsaturated compounds containing keto groups containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9704028A 1996-05-15 1997-05-09 Inhibition of matrix metalloproteinases by 2(w-aroylalkyl)-4-biaryl-4-oxobutyric acids. ZA974028B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64502996A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
ZA974028B true ZA974028B (en) 1998-02-19

Family

ID=24587374

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9704028A ZA974028B (en) 1996-05-15 1997-05-09 Inhibition of matrix metalloproteinases by 2(w-aroylalkyl)-4-biaryl-4-oxobutyric acids.

Country Status (22)

Country Link
EP (1) EP0904260B1 (de)
JP (1) JP3524556B2 (de)
CN (1) CN1119313C (de)
AR (1) AR007099A1 (de)
AT (1) ATE224350T1 (de)
AU (1) AU715877B2 (de)
BR (1) BR9709078A (de)
CA (1) CA2254750C (de)
CO (1) CO5011071A1 (de)
DE (1) DE69715619T2 (de)
ES (1) ES2184092T3 (de)
HN (1) HN1997000070A (de)
HR (1) HRP970242A2 (de)
ID (1) ID17938A (de)
PA (1) PA8429601A1 (de)
PE (1) PE66198A1 (de)
SV (1) SV1997000038A (de)
TN (1) TNSN97081A1 (de)
TW (1) TW457231B (de)
WO (1) WO1997043240A1 (de)
YU (1) YU18397A (de)
ZA (1) ZA974028B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TNSN97083A1 (fr) 1996-05-15 2005-03-15 Bayer Corp Inhibition des matrices metalloproteases par la substitution d'acide biaryl oxobutyrique
TNSN97085A1 (fr) 1996-05-15 2005-03-15 Bayer Corp Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease
HRP970243B1 (en) 1996-05-15 2002-06-30 Bayer Ag Inhibition of matrix metalloproteases by substituted phenethyl compounds
ZA974033B (en) 1996-05-15 1998-02-19 Bayer Ag Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors.
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (de) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Verwendung von substituierten 4-Biarylbuttersäuren und 5-Biarylpentansäuren zur Behandlung von zerebralen Krankheiten
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
US20170114049A1 (en) 2014-04-03 2017-04-27 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
CN116687925B (zh) * 2022-11-04 2024-10-22 中国科学院遗传与发育生物学研究所 一种侵蚀性蛋白酶抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS243570B1 (en) * 1984-08-31 1986-06-12 Miroslav Kuchar Omega-aryloxoalkane acids
GB9101468D0 (en) * 1991-01-23 1991-03-06 Ciba Geigy Coating compositions
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
CO5011071A1 (es) 2001-02-28
HN1997000070A (es) 1997-09-08
CA2254750C (en) 2003-09-30
EP0904260B1 (de) 2002-09-18
TW457231B (en) 2001-10-01
CN1119313C (zh) 2003-08-27
JP2001509783A (ja) 2001-07-24
BR9709078A (pt) 1999-08-03
ES2184092T3 (es) 2003-04-01
EP0904260A1 (de) 1999-03-31
AU715877B2 (en) 2000-02-10
DE69715619D1 (de) 2002-10-24
PE66198A1 (es) 1998-10-23
PA8429601A1 (es) 2000-05-24
TNSN97081A1 (fr) 2005-03-15
AU3010497A (en) 1997-12-05
HRP970242A2 (en) 1998-04-30
ID17938A (id) 1998-02-12
CN1234791A (zh) 1999-11-10
AR007099A1 (es) 1999-10-13
WO1997043240A1 (en) 1997-11-20
YU18397A (en) 1999-11-22
DE69715619T2 (de) 2003-01-16
CA2254750A1 (en) 1997-11-20
ATE224350T1 (de) 2002-10-15
SV1997000038A (es) 1998-09-01
JP3524556B2 (ja) 2004-05-10

Similar Documents

Publication Publication Date Title
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
PH31545A (en) Inhibition of helicobacter.
EP0601322A3 (de) Adenosindeaminaseinhibitor.
GB9325558D0 (en) Percaboxylic acids
PL324992A1 (en) Novel derivatives of 2,3-dioxotetrahydoquinoxaline
PL329121A1 (en) Substituted derivatives of 1,2,3,4-tetrahydronaphtalene
HU9502684D0 (en) 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkane-carboxylic acid derivatives
IL137162A0 (en) 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
ZA974030B (en) Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids.
PL340372A1 (en) Novel 3,6x-hemiketals of 9a-azalydes class
ZA931773B (en) Substituted phenylacetamides.
ZA974028B (en) Inhibition of matrix metalloproteinases by 2(w-aroylalkyl)-4-biaryl-4-oxobutyric acids.
ZA974029B (en) Inhibition of matrix metalloproteinases by substituted phenethyl compounds.
HU9400745D0 (en) 2,4-diamino-3-hydroxy-carboxylic acid derivatives
ZA974032B (en) Substituted oxobutyric acids as matrix metalloproteinases inhibitors.
EP0618222A3 (en) Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid.
PL330141A1 (en) Novel derivatives of 10,11-dihydro-10-oxo-5h-dibezyl(b,f)-azepin-5-carboxagmide
ZA974929B (en) New forms of organic salts of N'N-diacetylcystine.
AU5473694A (en) Nitrosamine inhibition
GB9510563D0 (en) Well inhibition
ZA965800B (en) Novel quinoxaline- and quinoxalinylalkane-phosphonic acids
ZA977916B (en) Method of inhibiting matrix metalloproteinases.
FI945105L (fi) 17alfa- ja 17beta-substituoitu estra-1,3,5(10)-trieeni-3-karboksyylihappo
Hinze Christopraxis: A Theology of Action